Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC
April 28th 2017David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).
Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC
April 25th 2017Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.
SIRT Better-Tolerated Than Sorafenib in Advanced HCC
April 22nd 2017Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC
April 22nd 2017Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).
Potential Biomarker for Survival Emerges in Hepatocellular Carcinoma
April 22nd 2017Log10 alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.
Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC
April 21st 2017David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.
Independent Prognostic Markers of HCC Recurrence Identified
April 21st 2017Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.
Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC
April 20th 2017Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.
HCC Risk Comparable in Hepatitis C Patients Treated With DAA or Interferon
April 20th 2017A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.